187 related articles for article (PubMed ID: 18690873)
21. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
McCormack PL; Plosker GL
Drugs; 2006; 66(5):711-28. PubMed ID: 16620148
[TBL] [Abstract][Full Text] [Related]
22. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
23. Effects of ibandronate on bone quality: preclinical studies.
Bauss F; Dempster DW
Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333
[TBL] [Abstract][Full Text] [Related]
24. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Heidenreich A; Ohlmann CH
Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
26. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
Body JJ; Diel IJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
Ann Oncol; 2003 Sep; 14(9):1399-405. PubMed ID: 12954579
[TBL] [Abstract][Full Text] [Related]
27. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
[TBL] [Abstract][Full Text] [Related]
28. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
Body JJ; Diel IJ; Lichinitzer M; Lazarev A; Pecherstorfer M; Bell R; Tripathy D; Bergstrom B
Br J Cancer; 2004 Mar; 90(6):1133-7. PubMed ID: 15026791
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
30. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
[TBL] [Abstract][Full Text] [Related]
31. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
Pecherstorfer M
Expert Opin Pharmacother; 2004 Nov; 5(11):2341-50. PubMed ID: 15500381
[TBL] [Abstract][Full Text] [Related]
33. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
Bauss F; Russell RG
Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
[TBL] [Abstract][Full Text] [Related]
34. Managing metastatic bone pain: the role of bisphosphonates.
Gralow J; Tripathy D
J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
36. Ibandronate reduces skeletal morbidity in patients with breast cancer.
Tripathy A D; Diel I; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
[TBL] [Abstract][Full Text] [Related]
37. Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.
Halvorson KG; Sevcik MA; Ghilardi JR; Sullivan LJ; Koewler NJ; Bauss F; Mantyh PW
J Pain Symptom Manage; 2008 Sep; 36(3):289-303. PubMed ID: 18411018
[TBL] [Abstract][Full Text] [Related]
38. Ibandronate.
Dooley M; Balfour JA
Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
[TBL] [Abstract][Full Text] [Related]
39. Review of ibandronate in the treatment of osteoporosis.
Chapurlat RD; Delmas PD
Expert Opin Pharmacother; 2003 Mar; 4(3):391-6. PubMed ID: 12614191
[TBL] [Abstract][Full Text] [Related]
40. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
